Uveal Melanoma - Pipeline Review, H1 2016

Published: Apr, 2016 | Pages: 115 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)

Uveal Melanoma - Pipeline Review, H1 2016

Summary

Global Markets Direct's, ‘Uveal Melanoma - Pipeline Review, H1 2016', provides an overview of the Uveal Melanoma pipeline landscape. 

The report provides comprehensive information on the therapeutics under development for Uveal Melanoma, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Uveal Melanoma and features dormant and discontinued projects. 

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape of Uveal Melanoma
- The report reviews pipeline therapeutics for Uveal Melanoma by companies and universities/research institutes based on information derived from company and industry-specific sources 
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages 
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities 
- The report reviews key players involved Uveal Melanoma therapeutics and enlists all their major and minor projects
- The report assesses Uveal Melanoma therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type 
- The report summarizes all the dormant and discontinued pipeline projects 
- The report reviews latest news related to pipeline therapeutics for Uveal Melanoma

Reasons to Buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage 
- Identify and understand important and diverse types of therapeutics under development for Uveal Melanoma
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies 
- Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Uveal Melanoma pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and Scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

 Table of Content
Table of Contents 2

List of Tables 6
List of Figures 7
Introduction 8
Global Markets Direct Report Coverage 8
Uveal Melanoma Overview 9
Therapeutics Development 10
Pipeline Products for Uveal Melanoma - Overview 10
Pipeline Products for Uveal Melanoma - Comparative Analysis 11
Uveal Melanoma - Therapeutics under Development by Companies 12
Uveal Melanoma - Therapeutics under Investigation by Universities/Institutes 13
Uveal Melanoma - Pipeline Products Glance 14
Late Stage Products 14
Clinical Stage Products 15
Early Stage Products 16
Uveal Melanoma - Products under Development by Companies 17
Uveal Melanoma - Products under Investigation by Universities/Institutes 18
Uveal Melanoma - Companies Involved in Therapeutics Development 19
Aura Biosciences, Inc. 19
Bellicum Pharmaceuticals, Inc. 20
Celldex Therapeutics, Inc. 21
Cleveland BioLabs, Inc. 22
Eli Lilly and Company 23
Immunocore Limited 24
Navigen Pharmaceuticals, Inc. 25
Novartis AG 26
PEP-Therapy SAS 27
Pfizer Inc. 28
Spectrum Pharmaceuticals, Inc. 29
Uveal Melanoma - Therapeutics Assessment 30
Assessment by Monotherapy Products 30
Assessment by Target 31
Assessment by Mechanism of Action 34
Assessment by Route of Administration 36
Assessment by Molecule Type 38
Drug Profiles 40
AU-011 - Drug Profile 40
Product Description 40
Mechanism of Action 40
R&D Progress 40
axitinib - Drug Profile 41
Product Description 41
Mechanism of Action 41
R&D Progress 41
BPX-701 - Drug Profile 45
Product Description 45
Mechanism of Action 45
R&D Progress 45
Cellular Immunotherapy to Target Melan-A, MAGE-3 and Survivin for Melanoma and Uveal Melanoma - Drug Profile 47
Product Description 47
Mechanism of Action 47
R&D Progress 47
crizotinib - Drug Profile 48
Product Description 48
Mechanism of Action 48
R&D Progress 48
DPTC-9h - Drug Profile 52
Product Description 52
Mechanism of Action 52
R&D Progress 52
emibetuzumab - Drug Profile 54
Product Description 54
Mechanism of Action 54
R&D Progress 54
entolimod - Drug Profile 55
Product Description 55
Mechanism of Action 55
R&D Progress 55
glembatumumab vedotin - Drug Profile 57
Product Description 57
Mechanism of Action 57
R&D Progress 57
IMCgp-100 - Drug Profile 59
Product Description 59
Mechanism of Action 59
R&D Progress 59
KCN-1 - Drug Profile 61
Product Description 61
Mechanism of Action 61
R&D Progress 61
LXS-196 - Drug Profile 63
Product Description 63
Mechanism of Action 63
R&D Progress 63
merestinib - Drug Profile 64
Product Description 64
Mechanism of Action 64
R&D Progress 64
NAV-2729 - Drug Profile 65
Product Description 65
Mechanism of Action 65
R&D Progress 65
nutlin-3 - Drug Profile 68
Product Description 68
Mechanism of Action 68
R&D Progress 68
pasireotide ER - Drug Profile 69
Product Description 69
Mechanism of Action 69
R&D Progress 69
sotrastaurin acetate - Drug Profile 71
Product Description 71
Mechanism of Action 71
R&D Progress 71
sunitinib malate - Drug Profile 73
Product Description 73
Mechanism of Action 73
R&D Progress 73
Vaccine 2 for Melanoma - Drug Profile 78
Product Description 78
Mechanism of Action 78
R&D Progress 78
Vaccine for Oncology - Drug Profile 79
Product Description 79
Mechanism of Action 79
R&D Progress 79
vincristine sulfate - Drug Profile 80
Product Description 80
Mechanism of Action 80
R&D Progress 80
Uveal Melanoma - Recent Pipeline Updates 83
Uveal Melanoma - Dormant Projects 107
Uveal Melanoma - Discontinued Products 108
Uveal Melanoma - Product Development Milestones 109
Featured News & Press Releases 109
Mar 30, 2016: Immunocore's IMCgp100 Starts Phase I Trial for the Treatment of Uveal Melanoma 109
Jan 25, 2016: Immunocore's IMCgp100 Granted Orphan Drug Designation by US FDA for the Treatment of Uveal Melanoma 109
Jan 11, 2016: Bellicum Pharmaceuticals Announces Submission of BPX-701 Clinical Trial Protocols for Review by the NIH RAC 110
Sep 09, 2015: Immunocore's IMCgp100 Accepted for Adaptive Pathway Pilot Programme 111
Jun 29, 2015: Lilly and Immunocore To Conduct Phase Ib/II Clinical Trial Collaboration For Treatment Of uveal melanoma 111
May 21, 2015: FDA Grants Orphan Drug Designation to Aura Biosciences' Novel Treatment for Uveal Melanoma 112
Appendix 114
Methodology 114
Coverage 114
Secondary Research 114
Primary Research 114
Expert Panel Validation 114
Contact Us 114
Disclaimer 115

List of Tables

Number of Products under Development for Uveal Melanoma, H1 2016 10
Number of Products under Development for Uveal Melanoma - Comparative Analysis, H1 2016 11
Number of Products under Development by Companies, H1 2016 12
Number of Products under Investigation by Universities/Institutes, H1 2016 13
Comparative Analysis by Late Stage Development, H1 2016 14
Comparative Analysis by Clinical Stage Development, H1 2016 15
Comparative Analysis by Early Stage Development, H1 2016 16
Products under Development by Companies, H1 2016 17
Products under Investigation by Universities/Institutes, H1 2016 18
Uveal Melanoma - Pipeline by Aura Biosciences, Inc., H1 2016 19
Uveal Melanoma - Pipeline by Bellicum Pharmaceuticals, Inc., H1 2016 20
Uveal Melanoma - Pipeline by Celldex Therapeutics, Inc., H1 2016 21
Uveal Melanoma - Pipeline by Cleveland BioLabs, Inc., H1 2016 22
Uveal Melanoma - Pipeline by Eli Lilly and Company, H1 2016 23
Uveal Melanoma - Pipeline by Immunocore Limited, H1 2016 24
Uveal Melanoma - Pipeline by Navigen Pharmaceuticals, Inc., H1 2016 25
Uveal Melanoma - Pipeline by Novartis AG, H1 2016 26
Uveal Melanoma - Pipeline by PEP-Therapy SAS, H1 2016 27
Uveal Melanoma - Pipeline by Pfizer Inc., H1 2016 28
Uveal Melanoma - Pipeline by Spectrum Pharmaceuticals, Inc., H1 2016 29
Assessment by Monotherapy Products, H1 2016 30
Number of Products by Stage and Target, H1 2016 32
Number of Products by Stage and Mechanism of Action, H1 2016 35
Number of Products by Stage and Route of Administration, H1 2016 37
Number of Products by Stage and Molecule Type, H1 2016 39
Uveal Melanoma Therapeutics - Recent Pipeline Updates, H1 2016 83
Uveal Melanoma - Dormant Projects, H1 2016 107
Uveal Melanoma - Discontinued Products, H1 2016 108